Quantcast
Last updated on April 17, 2014 at 9:25 EDT
UCSF Launches Groundbreaking Online Registry To Drive Brain

UCSF Launches Groundbreaking Online Registry To Drive Brain Disease Research

Laura Kurtzman, UC San Francisco Brain Health Registry Brings Promise of Faster, Better Clinical Trials, New Treatments A new online project led by researchers at UC San Francisco promises to dramatically cut the time and cost of conducting...

Latest Clinical research Stories

2014-04-17 00:21:10

DUBLIN, April 17, 2014 /PRNewswire/ -- Heart Metabolics Limited, a new Irish biotechnology company focused on development of drugs for cardio-metabolic diseases, has announced the completion of a $20 million Series A financing from venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill. The proceeds from this financing have supported Heart Metabolics Limited in acquiring a Phase 3-ready drug candidate and related preclinical drug...

2014-04-16 23:16:23

KRS Global Biotechnology, Inc. a specialty pharmacy preparing drugs no longer commercially available or in short supply announces today that they have become a registered Outsourcing Facility under the new Compounding Quality Act. Boca Raton, FL (PRWEB) April 16, 2014 KRS Global Biotechnology, Inc. is pleased to announce that it has been recognized as a registered 503B Large-scale sterile compounding “Outsourcing Facility” by the Food & Drug Administration (FDA) under the Drug...

2014-04-16 23:09:48

New webinar will focus on how to handle and prevent missing data to improve clinical trial data credibility. The live discussion takes place on Friday, May 2, 2014 at 10:00am EDT (15:00 UK BST/ GMT +1). Toronto, Canada (PRWEB) April 16, 2014 Missing data is common in most clinical trials because some subjects withdraw from the trial before the crucial final measurements. Without those final measurements, our picture of the new treatment is imperfect, and it could actually be wrong. What...

2014-04-16 23:08:20

Brody will lead Kantar Health’s partnerships and acquisitions activities. New York, NY (PRWEB) April 16, 2014 Kantar Health, a leading global healthcare consulting firm, has named Jeremy Brody as Executive Vice President, Corporate Development. In his new role, Brody will lead Kantar Health’s partnerships and acquisitions activities as well as continue to oversee the firm’s strategy for incorporating digital and mobile into its research programs. Brody is based near Tel Aviv,...

2014-04-16 16:13:04

New screening technique opens the door to unlimited opportunities, both in terms of chemistry and biology research Researchers at Griffith University's Eskitis Institute have developed a new technique for discovering natural compounds which could form the basis of novel therapeutic drugs. The corresponding author, Professor Ronald Quinn AM said testing the new process on a marine sponge had delivered not only confirmation that the system is effective, but also a potential lead in the...

2014-04-16 12:29:54

PLYMOUTH MEETING, Pa., April 16, 2014 /PRNewswire/ -- ePharmaSolutions, a leading provider of eClinical solutions announced the results of the initial pilot studies for its patient matching and triaging solution, ReferralPlus(TM), that suggest a significant improvement in match rates for people who are actively searching for clinical trials in which to participate. "We are absolutely thrilled with the results of these pilots and want to thank all of the pharmaceutical companies who helped...

2014-04-16 12:29:46

CHESTERFIELD, Mo., April 16, 2014 /PRNewswire/ -- Amid the FDA and ASHP announced shortages of unapproved Neostigmine Methylsulfate Injection; Eclat Pharmaceuticals is effectively ending the shortages with BLOXIVERZ®, the only FDA-approved Neostigmine Methylsulfate Injection. http://photos.prnewswire.com/prnvar/20140416/74458 BLOXIVERZ is available in two dosage strengths, 0.5 mg/mL and 1 mg/mL, in 10 mL multiple dose vials. All other Neostigmine Methylsulfate Injections are not...

2014-04-16 12:29:41

CHARLOTTE, N.C., April 16, 2014 /PRNewswire/ -- On April 10, 2014 the U.S. Food & Drug Administration (FDA) issued a "Closeout" letter to Prodigy Diabetes Care to formally conclude the regulatory action that resulted in a Warning Letter on February 22, 2013. Since the original site inspection of Prodigy in March 2012, and in response to the February 2013 letter, Prodigy has worked with the FDA to address and correct the issues identified through that inspection. The FDA Atlanta...

2014-04-16 08:34:21

Clinical Results Open Significant Market Opportunity for BioElectronics Corp. FREDERICK, Md., April 16, 2014 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices, announced reports on preliminary results of a randomized, double blind, placebo controlled trial on osteoarthritis of the knee (knee pain) using ActiPatch® Therapy. An abstract on the interim analysis of the osteoarthritis (OA) knee pain study has been accepted by...

2014-04-16 08:30:31

GERMANTOWN, Md., April 16, 2014 /PRNewswire/ -- -- Investment of $10 million in Germantown and Frederick campuses brings QIAGEN's total recent commitment in Maryland to $50 million -- Germantown campus becomes state-of-the-art research, manufacturing and office site for Molecular Diagnostics with consolidation of activities from Gaithersburg site -- Germantown site passes FDA pre-approval inspection to manufacture digene HC2 HPV Test --...